Share on LinkedInShare on LinkedIn

ARTICLE · 29 NOVEMBER 2016

Pharmaceutical Product Liability Class Action Filed Relating To Olmetec Drug

Bennett Jones LLP
Bennett Jones LLP
Contributor
Bennett Jones LLP

Bennett Jones LLP

Bennett Jones is one of Canada’s premier business law firms. With deep experience in complex...

View firm profile
Explore more from Bennett Jones LLP

Earlier this month a proposed class action was filed in Montreal by the Consumer Law Group alleging that Merck, Shering-Plough and Daiichi Sankyo provided inadequate warnings...

CanadaConsumer Protection

Earlier this month a proposed class action was filed in Montreal by the Consumer Law Group alleging that Merck, Shering-Plough and Daiichi Sankyo (the Defendants) provided inadequate warnings about the drugs Olmetec and Olmetec Plus (together, Olmetec), which are allegedly designed, manufactured, distributed and marketed by the Defendants.

The motion for authorization to bring a class action contemplates a national class that includes all persons who were prescribed and have ingested Olmetec. Though the motion for authorization makes a passing defective design allegation, the defective design claim does not seem to be seriously advanced. Rather, the claim centers around the defendants' alleged failure to warn of gastrointestinal side effects associated with Olmetec.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from